ESTEVE Pharmaceuticals is an international pharmaceutical company committed to improving patient care through innovation and solution led thinking. 

Following our acquisition of HRA Pharma Rare Diseases in late 2024, we are streamlining our portfolio to deliver innovative programmes that empower healthcare professionals and optimise patient experience. The unified portfolio will address and focus on key therapeutic areas:

• Endocrinology and Oncology: Rare endocrine disorders and complex malignancies.
• Pain Management: Non-opioid therapies. 

This unified approach strengthens our mission to address unmet medical needs and deliver impactful patient care worldwide.